Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials Pharmaceutical TechnologyThe FDA requires Eli Lilly to evaluate "unexpected serious" risks associated with Foundayo - some of which have been addressed by the ACHIEVE-4 trial.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Roche to start new Elevidys study following setback in EuropeNext: Lilly’s new obesity pill passes heart safety test in diabetes Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
